

## Supplementary Material

**Article Title:** Improvements Over Time with Valbenazine in Elderly Adults ( $\geq 65$  Years) with Tardive Dyskinesia: Post Hoc Analyses of 2 Long-Term Studies

**Authors:** Martha Sajatovic, MD; George S. Alexopoulos, MD; Eric Jen, PharmD; Khody Farahmand, PharmD; Celia Zinger, MD

**DOI Number:** 10.4088/JCP.24m15550

### **LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE**


1. [Figure 1](#) Study Design
2. [Table 1](#) Psychiatric and Movement Scales Mean Score Change from Baseline to Week 48 by Age and Dose

### **DISCLAIMER**

This Supplementary Material has been provided by the authors as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

## SUPPLEMENTARY MATERIALS

**Supplementary Figure 1. Study Design**



Gray boxes indicate pooled study visits.

<sup>a</sup> Participants who initially received placebo in KINECT 3 were excluded.

<sup>b</sup> In KINECT 3, participants continued taking the valbenazine dose to which they were originally randomized. In KINECT 4, participants were escalated from 40 to 80 mg at Week 4 based on treatment response and tolerability. In both studies, dose reduction from 80 to 40 mg was allowed if tolerability issues arose.

BL, baseline; DBPC, double-blind placebo-controlled.

**Supplementary Table 1. Psychiatric and Movement Scales Mean Score Change from Baseline to Week 48 by Age and Dose**

	<65 years						≥65 years					
	VBZ 40 mg		VBZ 80 mg <sup>a</sup>		All VBZ <sup>b</sup>		VBZ 40 mg		VBZ 80 mg <sup>a</sup>		All VBZ <sup>b</sup>	
	n	Mean Change (SD)	n	Mean Change (SD)	n	Mean Change (SD)	n	Mean Change (SD)	n	Mean Change (SD)	n	Mean Change (SD)
<b>Psychiatric scales</b>												
PANSS total <sup>c</sup>	34	-1.9 (11.5)	71	-3.1 (7.9)	105	-2.7 (9.2)	6	-9.8 (12.9)	11	-3.8 (7.9)	17	-5.9 (10.0)
PANSS positive symptoms <sup>c</sup>	34	-0.6 (2.9)	71	-0.6 (2.8)	105	-0.6 (2.8)	6	-3.2 (2.3)	11	-0.5 (2.8)	17	-1.4 (2.9)
PANSS negative symptoms <sup>c</sup>	34	-0.4 (4.7)	71	-0.6 (2.9)	105	-0.5 (3.6)	6	-1.5 (4.7)	11	-0.5 (2.4)	17	-0.9 (3.3)
CDSS total <sup>c</sup>	34	0 (2.1)	71	-0.7 (2.5)	105	-0.5 (2.4)	6	-1.0 (1.6)	11	0 (2.3)	17	-0.4 (2.1)
YMRS total <sup>d</sup>	13	-1.4 (3.1)	34	-1.1 (2.5)	47	-1.2 (2.7)	2	-1.5 (0.7)	9	0.2 (1.4)	11	-0.1 (1.5)
MADRS total <sup>d</sup>	13	1.2 (4.9)	34	0.9 (6.2)	47	1.0 (5.8)	2	0 (0)	9	-3.1 (3.7)	11	-2.5 (3.5)
<b>Movement scales</b>												
BARS total	47	-0.7 (1.9)	104	-0.9 (1.8)	151	-0.8 (1.9)	8	-0.6 (1.2)	20	-0.6 (1.1)	28	-0.6 (1.1)
BARS global	47	-0.2 (1.0)	105	-0.4 (0.8)	152	-0.3 (0.9)	8	-0.4 (0.7)	20	-0.3 (0.6)	28	-0.3 (0.6)
SAS global	47	-0.1 (0.2)	105	-0.1 (0.3)	152	-0.1 (0.2)	8	0 (0.1)	20	-0.1 (0.2)	28	-0.1 (0.1)

<sup>a</sup> Includes participants who had a dose reduction from 80 mg to 40 mg.

<sup>b</sup> No statistical significance between age subgroups was found for outcomes in all valbenazine-treated participants.

<sup>c</sup> In patients with a diagnosis of schizophrenia or schizoaffective disorder.

<sup>d</sup> In patients with a diagnosis of mood disorder, including bipolar disorder and major depressive disorder.

BARS, Barnes Akathisia Rating Scale; CDSS, Calgary Depression Scale for Schizophrenia; MADRS, Montgomery-Åsberg Depression Rating Scale; PANSS, Positive and Negative Syndrome Scale; SAS, Simpson-Angus Scale; SD, standard deviation; VBZ, valbenazine; YMRS, Young Mania Rating Scale.